(Q38243206)

31 August 2017

title

Antimicrobial treatment of non-cystic fibrosis bronchiectasis (English)

1 reference

31 August 2017

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Anne B Chang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1

Keith Grimwood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

26 August 2014

1 reference

Expert Review of Anti-infective Therapy

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

1277-1296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

Does failed chronic wet cough response to antibiotics predict bronchiectasis?

6 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

New Zealand national incidence of bronchiectasis "too high" for a developed country.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Differences and similarities in non-cystic fibrosis bronchiectasis between developing and affluent countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Chronic suppurative lung disease in a developing country: impact on child and parent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Trends in bronchiectasis mortality in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis in patients with COPD: a distinct COPD phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Qualitative analysis of high-resolution CT scans in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Mortality in bronchiectasis: a long-term study assessing the factors influencing survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Aetiology in adult patients with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Immunity and bacterial colonisation in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchoscopy contributes to the clinical management of indigenous children newly diagnosed with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Airway microbiology and host defences in paediatric non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Adenovirus species C is associated with chronic suppurative lung diseases in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Microbiologic follow-up study in adult bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Non-tuberculous mycobacteria in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Pseudomonas aeruginosa: new insights into pathogenesis and host defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Mycobacterium abscessus: a new antibiotic nightmare

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Epidemiology of severe pediatric adenovirus lower respiratory tract infections in Manitoba, Canada, 1991-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

High rhinovirus burden in lower airways of children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Microbes in bronchiectasis: the forest or the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Assessing response to treatment of exacerbations of bronchiectasis in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

British Thoracic Society guideline for non-CF bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

The evidence base for non-CF bronchiectasis is finally evolving

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis: the arrival of better evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Longitudinal study of lung function in a cohort of primary ciliary dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Exacerbations in cystic fibrosis: 4--Non-cystic fibrosis bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Exacerbations in noncystic fibrosis bronchiectasis: Clinical features and investigations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Evaluating success of therapy for bronchiectasis: what end points to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis: an update on current pharmacotherapy and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Risks associated with the therapeutic use of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Impact of symptoms of anxiety and depression on COPD Assessment Test scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effectiveness of hospital-wide methicillin-resistant Staphylococcus aureus (MRSA) infection control policies differs by ward specialty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Staphylococcal decolonisation: an effective strategy for prevention of infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Antimicrobial therapy for bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Azithromycin: mechanisms of action and their relevance for clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Azithromycin and the risk of cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Use of azithromycin and death from cardiovascular causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Macrolide antibiotics and the risk of cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Longitudinal nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in indigenous Australian and Alaska native children with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Inhaled antibiotics for lower airway infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Bronchiectasis. Third report on a follow-up study of medical and surgical cases from childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a random

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Vaccines for Pseudomonas aeruginosa: a long and winding road

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

A novel microbiota stratification system predicts future exacerbations in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

The bronchiectasis severity index. An international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Treatment adherence and health outcomes in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Efficacy of Antibiotic Therapy for Acute Exacerbations of Mild to Moderate Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐Resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

Respiratory Bacterial Pathogens in the Nasopharynx and Lower Airways of Australian Indigenous Children with Bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2014.952282

10.1586/14787210.2014.952282

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25156239%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

1 reference